Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Sri Lanka’s hotel and tourism sector, a vital foreign exchange earner, faces a mounting labour shortage. A new study by the ...

MADISON, Wis. - Achieving the dream of playing college basketball was on the goal list of Nick Boyd throughout a star-studded prep career in New Jersey. Experie ...

Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) stock fell 22% after the company announced that its ESSENCE study for ultra-rare disease therapies AMONDYS 45 and VYONDYS 53 failed to achieve ...

"While the ESSENCE study did not meet statistical significance on its primary endpoint, we believe the results demonstrated a clear treatment effect, showing clinically meaningful functional outcomes ...

Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...

Osteoarthritis is now affecting younger adults, even in their 20s and 30s, moving beyond its traditional association with the ...

Thank you, operator. Good morning and good afternoon, everybody, and thank you for joining BioNTech's Third Quarter 2025 Earnings Call. As a reminder, the slides we'll use during the call and the ...

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Wendy Snyder (in for Bob Sirott) to discuss if hormone therapy can be beneficial when menopause begins, what we need to know ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full ...

“CrossFit is a combination of all kinds of movements that are pulled from weightlifting, gymnastics and cardio,” said Delgado, president of West Chester University’s (WCU) CrossFit Club. “There’s more ...

Shares in US health insurers struggled after the release of third quarter results, which were marked by rising costs and ...